Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.99 | 2.99 | 0.00 |
Shares | 97.01 | 97.01 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 21.73 | 23.85 |
Price to Book | 4.88 | 4.49 |
Price to Sales | 3.69 | 3.28 |
Price to Cash Flow | 14.29 | 15.78 |
Dividend Yield | 1.20 | 1.25 |
5 Years Earnings Growth | 14.02 | 12.58 |
Name | Net % | Category Average |
---|---|---|
Financial Services | 25.24 | 13.55 |
Healthcare | 19.03 | 16.35 |
Technology | 16.02 | 26.61 |
Communication Services | 13.23 | 8.05 |
Consumer Defensive | 12.96 | 7.85 |
Industrials | 7.21 | 11.91 |
Consumer Cyclical | 6.32 | 12.50 |
Number of long holdings: 34
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Visa A | US92826C8394 | 6.59 | 270.66 | -0.20% | |
Alphabet A | US02079K3059 | 6.49 | 176.79 | +0.93% | |
Mastercard | US57636Q1040 | 5.58 | 444.63 | -0.08% | |
Microsoft | US5949181045 | 5.46 | 442.57 | +0.22% | |
Heineken | NL0000008977 | 4.90 | 76.55 | +0.53% | |
Fiserv | US3377381088 | 4.84 | 148.94 | +0.46% | |
Roche Holding Participation | CH0012032048 | 4.70 | 247.60 | +0.73% | |
Meta Platforms | US30303M1027 | 4.53 | 504.16 | +0.11% | |
Experian | GB00B19NLV48 | 4.45 | 3,707.0 | -0.35% | |
Agilent Technologies | US00846U1016 | 3.73 | 129.85 | -0.55% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GB00BZ6CNS31 | 2.08B | -2.31 | 7.23 | - | ||
Troy Trojan O Acc | 975.38M | 0.08 | 4.21 | 5.18 | ||
Troy Trojan O Inc | 219.64M | 0.08 | 4.21 | 5.18 | ||
Troy Trojan S Acc | 72.46M | 0.13 | 4.48 | 5.45 | ||
Troy Trojan S Inc | 152.8M | 0.12 | 4.47 | 5.46 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review